Compare RSI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSI | ABCL |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2020 | 2020 |
| Metric | RSI | ABCL |
|---|---|---|
| Price | $26.26 | $10.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $28.20 | $8.40 |
| AVG Volume (30 Days) | 2.8M | ★ 9.0M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 933.33 | 10.91 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,134,428,000.00 | $75,128,000.00 |
| Revenue This Year | $25.44 | N/A |
| Revenue Next Year | $14.27 | $21.85 |
| P/E Ratio | $135.79 | ★ N/A |
| Revenue Growth | 22.76 | ★ 160.56 |
| 52 Week Low | $15.51 | $2.75 |
| 52 Week High | $34.53 | $12.15 |
| Indicator | RSI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 66.21 |
| Support Level | $26.00 | $3.38 |
| Resistance Level | $28.77 | N/A |
| Average True Range (ATR) | 1.14 | 0.90 |
| MACD | 0.18 | 0.23 |
| Stochastic Oscillator | 46.54 | 77.49 |
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.